1261225-49-3

Usage

Uses

Used in Pharmaceutical Industry:
[3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester is used as a potential inhibitor or modulator for enzymatic reactions or biochemical processes. Its unique structure, including the cyclohexyl, benzyloxycarbonyl, and tertbutyl ester groups, may allow it to interact with specific enzymes or biological targets, making it a candidate for the development of new drugs or therapies.
Used in Research and Development:
In the field of research and development, [3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester can be utilized as a starting material or intermediate in the synthesis of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science. Its unique structural features may enable the development of novel compounds with specific biological activities or properties.

Upstream product

• 100-51-6 benzyl alcohol 
• 1259278-11-9 benzyl N-[(1S,3R)-3-carbamoylcyclohexyl]carbamate 
• 1907-33-1 lithium tert-butoxide 
• 2305-30-8 (1R)-cyclohexane-1,3-dicarboxylic acid 
• 4355-31-1 3-oxabicyclo<3.3.1>nonane-2,4-dione 
• 62059-56-7 cis-1,3-Cyclohexanedicarboxylic acid diethyl ester 
• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 
• 1223158-00-6 benzyl cis-3-(aminocyclohexyl)carbamate 
• 498532-32-4 C₆H₁₄N₂*2ClH 
• 3385-21-5 1,3-diaminocyclohexane 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 347186-01-0 N-(3-aminocyclohexyl)(t-butoxy)carboxamide 
• 501-53-1 benzyl chloroformate 
• 53084-60-9 ethyl (1R,3S)-3-aminocyclohexanecarboxylate 

Downstream Products

• 1259278-17-5 tert-butyl N-[(1R,3S)-3-aminocyclohexyl]carbamate 
• 1298101-49-1 C₂₈H₃₅N₅O₅ 
• 1383485-60-6 C₁₆H₂₂BrF₂N₃O₂ 
• 1383485-61-7 (1S,3R)-N₁-(6-bromo-3,5-difluoropyridin-2-yl)cyclohexane-1,3-diamine 
• 1298101-47-9 ((1S,3R)-3-aminocyclohexyl)carbamic acid tert-butyl ester 
• 1222709-28-5 ((1S,3R)-3-aminocyclohexyl)benzylcarbamate hydrochloride 
• 1259279-62-3 N-[(1R,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]-pyridin-3-yl)pyrimidin-4-yl]amino]cyclohexyl]morpholine-4-carboxamide 

Relevant academic research and scientific papers

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

Pyrimidine amine compound, and preparation method and application thereof

The invention discloses a polycyclic compound, and a preparation method and an application thereof. The invention provides the polycyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof. The compound has a relatively good inhibition effect on CDK7.

Heteroaromatic nitrile compound and application thereof

The invention discloses a heteroaromatic nitrile compound and application thereof. The invention provides a heteroaromatic nitrile compound shown as formula I or a pharmaceutically acceptable salt thereof. The compound has a good inhibition effect on CDK7.

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

HETEROCYCLIC INDOLES FOR USE IN INFLUENZA VIRUS INFECTION

The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.

Development of a Scalable Synthesis of an Azaindolyl-Pyrimidine Inhibitor of Influenza Virus Replication

A scalable, asymmetric route for the synthesis of the influenza virus replication inhibitor 2 is presented. The key steps include an enzymatic desymmetrization of cis-1,3-cyclohexanediester in 99% yield and 96% ee, SNAr displacement of a methanesulfinylpyrimidine, and a Curtius rearrangement to form a morpholinyl urea. This high-yielding route allowed us to rapidly synthesize hundreds of grams of 2 in 99% purity to support in vivo studies.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Compound according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. Uses of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.